The weekly combined immunotherapy of locally administrated CVV and systemically administrated anti-PD-1 synergistically induces CD8+ PD-1+ T-cell infiltration in the TME, which might be associated with tumor regression in a syngeneic immunocompetent mouse CRC model. Here, CD8A is linked to neoplasm.